Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors.
Liu S, Zhou F, Liu Z, Xiong A, Jia Y, Zhao S, Zhao C, Li X, Jiang T, Han R, Qiao M, Liu Y, He Y, Li J, Li W, Gao G, Ren S, Su C, Zhou C. Liu S, et al. Among authors: gao g. Transl Lung Cancer Res. 2020 Aug;9(4):1053-1066. doi: 10.21037/tlcr-19-396. Transl Lung Cancer Res. 2020. PMID: 32953484 Free PMC article.
Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer.
Jia Y, Jiang T, Li X, Zhao C, Zhang L, Zhao S, Liu X, Qiao M, Luo J, Shi J, Yang H, Wang Y, Xi L, Zhang S, Gao G, Su C, Ren S, Zhou C. Jia Y, et al. Among authors: gao g. Oncol Lett. 2017 Dec;14(6):6525-6532. doi: 10.3892/ol.2017.7016. Epub 2017 Sep 21. Oncol Lett. 2017. PMID: 29163686 Free PMC article.
Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.
Jiang T, Li X, Wang J, Su C, Han W, Zhao C, Wu F, Gao G, Li W, Chen X, Li J, Zhou F, Zhao J, Cai W, Zhang H, Du B, Zhang J, Ren S, Zhou C, Yu H, Hirsch FR. Jiang T, et al. Among authors: gao g. Theranostics. 2017 Oct 17;7(19):4753-4762. doi: 10.7150/thno.21687. eCollection 2017. Theranostics. 2017. PMID: 29187901 Free PMC article. Clinical Trial.
Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma.
Liu Y, Dong Z, Jiang T, Hou L, Wu F, Gao G, He Y, Zhao J, Li X, Zhao C, Zhang W, Tian Q, Pan Y, Wang Y, Yang S, Wu C, Ren S, Zhou C, Zhang J, Hirsch FR. Liu Y, et al. Among authors: gao g. Clin Lung Cancer. 2018 Jul;19(4):e421-e430. doi: 10.1016/j.cllc.2018.02.008. Epub 2018 Mar 31. Clin Lung Cancer. 2018. PMID: 29609906
EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
Liu S, He Y, Jiang T, Ren S, Zhou F, Zhao C, Li X, Zhang J, Su C, Chen X, Cai W, Gao G, Li W, Wu F, Li J, Zhao J, Hu Q, Zhao M, Zhou C, Hirsch FR. Liu S, et al. Among authors: gao g. Lung Cancer. 2018 Jun;120:82-87. doi: 10.1016/j.lungcan.2018.04.004. Epub 2018 Apr 4. Lung Cancer. 2018. PMID: 29748021
EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
Jiang T, Chu Q, Wang H, Zhou F, Gao G, Chen X, Li X, Zhao C, Xu Q, Li W, Wu F, Xiong A, Zhao J, Xu Y, Su C, Ren S, Zhou C, Hirsch FR. Jiang T, et al. Among authors: gao g. Int J Cancer. 2019 May 15;144(10):2605-2612. doi: 10.1002/ijc.31962. Epub 2018 Dec 8. Int J Cancer. 2019. PMID: 30387880 Free article.
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Wang Y, Jiang T, Qin Z, Jiang J, Wang Q, Yang S, Rivard C, Gao G, Ng TL, Tu MM, Yu H, Ji H, Zhou C, Ren S, Zhang J, Bunn P, Doebele RC, Camidge DR, Hirsch FR. Wang Y, et al. Among authors: gao g. Ann Oncol. 2019 Mar 1;30(3):447-455. doi: 10.1093/annonc/mdy542. Ann Oncol. 2019. PMID: 30596880 Free PMC article. Clinical Trial.
Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer.
Pan Y, Gao G, Chen X, Tian Q, Wu F, Liu Q, Wang Y, Jiang T, Liu Y, Li X, Yang S, Xu C, Su C, Zhou F, Ren S, Zhou C. Pan Y, et al. Among authors: gao g. Thorac Cancer. 2019 Apr;10(4):686-694. doi: 10.1111/1759-7714.12986. Epub 2019 Feb 22. Thorac Cancer. 2019. PMID: 30793872 Free PMC article.
Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S, Mao S, Li X, Zhao C, Liu Q, Yu X, Wang Y, Liu Y, Pan Y, Wang C, Gao G, Li W, Xiong A, Chen B, Sun H, He Y, Wu F, Chen X, Su C, Ren S, Zhou C. Yang S, et al. Among authors: gao g. Lung Cancer. 2020 Jan;139:133-139. doi: 10.1016/j.lungcan.2019.11.018. Epub 2019 Nov 24. Lung Cancer. 2020. PMID: 31786475 Clinical Trial.
6,186 results